Forward Pharma A/S (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 00090 - Document - Document and Entity Information Network

*

*

 http://forward-pharma.com/role/DocumentDocumentAndEntityInformation
2 Implied Table Table

*

*

 implied:Table
3 Document and Entity Information [Abstract] Abstract fwp:DocumentAndEntityInformationAbstract
4 Entity Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
5 Entity Central Index Key Concept (CIK Number) For Period dei:EntityCentralIndexKey
6 Document Type Concept (Submission Type) For Period dei:DocumentType
7 Document Period End Date Concept (Date) For Period dei:DocumentPeriodEndDate
8 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
9 Current Fiscal Year End Date Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
10 Entity Well-known Seasoned Issuer Concept (Yes/No) For Period dei:EntityWellKnownSeasonedIssuer
11 Entity Voluntary Filers Concept (Yes/No) For Period dei:EntityVoluntaryFilers
12 Entity Current Reporting Status Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
13 Entity Filer Category Concept (Filer Category) For Period dei:EntityFilerCategory
14 Entity Common Stock, Shares Outstanding Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
15 Entity Shell Company Concept (Yes/No) For Period dei:EntityShellCompany
16 Entity Emerging Growth Company Concept (Yes/No) For Period dei:EntityEmergingGrowthCompany
17 Entity Ex Transition Period Concept (Yes/No) For Period dei:EntityExTransitionPeriod
18 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
19 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
20 00100 - Statement - Consolidated Statement of Financial Position Network

*

*

 http://forward-pharma.com/role/StatementConsolidatedStatementOfFinancialPosition
21 Implied Table Table

*

*

 implied:Table
22 Consolidated Statement of Financial Position Abstract ifrs-full:StatementOfFinancialPositionAbstract
23 Assets Abstract ifrs-full:AssetsAbstract
24 Non-current Assets: Abstract ifrs-full:NoncurrentAssetsAbstract
25 Equipment Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
26 Other non-current asset Concept (Monetary) As Of Debit ifrs-full:OtherNoncurrentAssets
27 Total non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssets
28 Prepayments Concept (Monetary) As Of Debit ifrs-full:Prepayments
29 Other receivables Concept (Monetary) As Of Debit ifrs-full:OtherCurrentReceivables
30 Income tax receivable Concept (Monetary) As Of Debit ifrs-full:CurrentTaxAssetsCurrent
31 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
32 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
33 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
34 Equity and Liabilities Abstract ifrs-full:EquityAndLiabilitiesAbstract
35 Share capital Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
36 Other components of equity: Abstract ifrs-full:MiscellaneousEquityAbstract
37 Foreign currency translation reserve Concept (Monetary) As Of Credit ifrs-full:ReserveOfExchangeDifferencesOnTranslation
38 Accumulated deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
39 Equity attributable to shareholders of the Parent Concept (Monetary) As Of Credit ifrs-full:EquityAttributableToOwnersOfParent
40 Total equity Concept (Monetary) As Of Credit ifrs-full:Equity
41 Non-current liabilities: Abstract ifrs-full:NoncurrentLiabilitiesAbstract
42 Deferred tax Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilities
43 Total non-current liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentLiabilities
44 Trade payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
45 Income tax payable Concept (Monetary) As Of Credit ifrs-full:CurrentTaxLiabilitiesCurrent
46 Accrued liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
47 Total current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
48 Total equity and liabilities Concept (Monetary) As Of Credit ifrs-full:EquityAndLiabilities
49 00200 - Statement - Consolidated Statement of Profit or Loss Network

*

*

 http://forward-pharma.com/role/StatementConsolidatedStatementOfProfitOrLoss
50 Implied Table Table

*

*

 implied:Table
51 Consolidated Statement of Profit or Loss Abstract ifrs-full:IncomeStatementAbstract
52 Revenue from settlement and license agreement Concept (Monetary) For Period Credit ifrs-full:Revenue
53 Cost of the Aditech Pharma AG agreement Concept (Monetary) For Period Debit ifrs-full:RoyaltyExpense
54 Research and development costs Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
55 General and administrative costs Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
56 Operating (loss) income Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
57 Exchange rate gain (loss), net Concept (Monetary) For Period Credit fwp:NetExchangeRateGainLoss
58 Interest income from available-for-sale financial assets Concept (Monetary) For Period Credit ifrs-full:InterestIncomeOnAvailableforsaleFinancialAssets
59 Other finance income (expense) Concept (Monetary) For Period Credit ifrs-full:OtherFinanceIncomeCost
60 (Loss) income before taxes Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
61 Income tax benefit (expense) Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
62 Net (loss) income for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
63 Net (loss) income for the year attributable to: Abstract ifrs-full:ProfitLossAttributableToAbstract
64 Equity holders of the Parent Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToOwnersOfParent
65 Per share amounts: Abstract ifrs-full:EarningsPerShareAbstract
66 Net (loss) income per share basic Concept (Share) For Period ifrs-full:BasicEarningsLossPerShare
67 Net (loss) income per share diluted Concept (Share) For Period ifrs-full:DilutedEarningsLossPerShare
68 00300 - Statement - Consolidated Statement of Other Comprehensive (Loss) Income Network

*

*

 http://forward-pharma.com/role/StatementConsolidatedStatementOfOtherComprehensiveLossIncome
69 Implied Table Table

*

*

 implied:Table
70 Consolidated Statement of Other Comprehensive (Loss) Income Abstract ifrs-full:StatementOfComprehensiveIncomeAbstract
71 Net (loss) income for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
72 Other comprehensive (loss) income to be reclassified to profit or loss in subsequent periods: Abstract ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract
73 Change in fair value of available-for-sale financial assets Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets
74 Exchange differences on translation of foreign operations Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
75 Net other comprehensive (loss) income to be reclassified to profit or loss in subsequent periods Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
76 Other comprehensive (loss) income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
77 Total comprehensive (loss) income Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
78 Attributable to: Abstract ifrs-full:ComprehensiveIncomeAttributableToAbstract
79 Equity holders of the Parent Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
80 00400 - Statement - Consolidated Statement of Changes in Shareholders' Equity Network

*

*

 http://forward-pharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity
81 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
82 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
83 Equity [member] Member ifrs-full:EquityMember
84 Equity attributable to owners of parent [member] Member ifrs-full:EquityAttributableToOwnersOfParentMember
85 Share capital Member ifrs-full:IssuedCapitalMember
86 Share premium Member ifrs-full:SharePremiumMember
87 Foreign currency translation reserve Member ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember
88 Fair value adjustment available - for - sale financial assets Member ifrs-full:ReserveOfGainsAndLossesOnRemeasuringAvailableforsaleFinancialAssetsMember
89 Accumulated deficit Member ifrs-full:RetainedEarningsMember
90 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
91 Equity at beginning of period Concept (Monetary) As Of Credit ifrs-full:Equity
92 Net (loss) income for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
93 Other comprehensive income (loss) Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
94 Total comprehensive (loss) income Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
95 Shareholder distribution Concept (Monetary) For Period Debit ifrs-full:ReductionOfIssuedCapital
96 Issuance of deferred shares Concept (Monetary) For Period Credit fwp:IssuanceOfDeferredShares
97 Exercise of warrants Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
98 Distribution to equity award holders Concept (Monetary) For Period Debit fwp:DistributionsToEquityAwardHolders
99 Share-based payment costs Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
100 Tax benefit resulting from share-based payment costs Concept (Monetary) For Period Debit ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
101 Transactions with owners Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
102 Equity at end of period Concept (Monetary) As Of Credit ifrs-full:Equity
103 00500 - Statement - Consolidated Statement of Cash Flows Network

*

*

 http://forward-pharma.com/role/StatementConsolidatedStatementOfCashFlows
104 Implied Table Table

*

*

 implied:Table
105 Consolidated Statement of Cash Flows Abstract ifrs-full:StatementOfCashFlowsAbstract
106 Operating activities: Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
107 (Loss) income before tax Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
108 Adjustments to reconcile (loss) income before tax to net cash flows (used in) provided by operating activities: Abstract ifrs-full:AdjustmentsForReconcileProfitLossAbstract
109 Share - based payment costs Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
110 Depreciation expense Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDepreciationExpense
111 Other including foreign exchange rate gain (loss) Concept (Monetary) For Period Credit fwp:OtherFinanceAdjustmentsIncludingForeignExchangeRateGainLoss
112 Cash inflow from interest on available-for-sale financial assets Concept (Monetary) For Period Debit ifrs-full:InterestReceivedClassifiedAsOperatingActivities
113 Cash inflow for taxes Concept (Monetary) For Period Debit ifrs-full:IncomeTaxesRefundClassifiedAsOperatingActivities
114 Cash (outflow) for taxes Concept (Monetary) For Period Credit ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
115 Decrease in other receivables and prepayments Concept (Monetary) For Period Debit fwp:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivablesAndPrepayments
116 (Decrease) increase in trade and other payables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
117 Net cash flows (used in) provided by operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
118 Investing activities: Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
119 Proceeds from the maturity of available-for-sale financial assets Concept (Monetary) For Period Debit ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets
120 Reduction in non-current asset Concept (Monetary) For Period Debit fwp:ReductionInNonCurrentAsset
121 Purchase of equipment Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
122 Net cash flows provided by investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
123 Financing activities: Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
124 Shares issued for cash Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
125 Shareholder distribution Concept (Monetary) For Period Credit ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
126 Repurchase of equity awards Concept (Monetary) For Period Credit fwp:PaymentsForRepurchaseOfEquityAwards
127 Net cash flows (used in) provided by financing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
128 Net (decrease) increase in cash and cash equivalents Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
129 Net foreign exchange differences Concept (Monetary) For Period Debit ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
130 Cash and cash equivalents at beginning of period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
131 Cash and cash equivalents at end of period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
132 10101 - Disclosure - Corporate information Network

*

*

 http://forward-pharma.com/role/DisclosureCorporateInformation
133 Implied Table Table

*

*

 implied:Table
134 Corporate information Abstract fwp:CorporateInformationAbstract
135 Corporate information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
136 10201 - Disclosure - Basis of Presentation Network

*

*

 http://forward-pharma.com/role/DisclosureBasisOfPresentation
137 Implied Table Table

*

*

 implied:Table
138 Basis of Preparation Abstract fwp:BasisOfPreparationAbstract
139 Basis of Presentation Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
140 10301 - Disclosure - Results for the Year Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYear
141 Implied Table Table

*

*

 implied:Table
142 Results for the Year Abstract fwp:DisclosureOfOperatingResultsAbstract
143 Results for the Year Concept (Text Block (HTML)) For Period fwp:DisclosureOfOperatingResultsTextBlock
144 10401 - Disclosure - Operating Assets and Liabilities Network

*

*

 http://forward-pharma.com/role/DisclosureOperatingAssetsAndLiabilities
145 Implied Table Table

*

*

 implied:Table
146 Operating Assets and Liabilities Abstract fwp:OperatingAssetsAndLiabilitiesAbstract
147 Operating Assets and Liabilities Concept (Text Block (HTML)) For Period fwp:OperatingAssetsAndLiabilitiesTextBlock
148 10501 - Disclosure - Capital Structure and Related Items Network

*

*

 http://forward-pharma.com/role/DisclosureCapitalStructureAndRelatedItems
149 Implied Table Table

*

*

 implied:Table
150 Capital Structure and Related Items Abstract fwp:CapitalStructureFinancialRiskManagementAndRelatedItemsAbstract
151 Capital Structure and Related Items Concept (Text Block (HTML)) For Period fwp:DisclosureOfCapitalStructureFinancialRiskManagementAndRelatedItemsTextBlock
152 10601 - Disclosure - Other Disclosures Network

*

*

 http://forward-pharma.com/role/DisclosureOtherDisclosures
153 Implied Table Table

*

*

 implied:Table
154 Other Disclosures Abstract ifrs-full:AdditionalInformationAbstract
155 Other Disclosures Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAdditionalInformationExplanatory
156 20202 - Disclosure - Basis of Preparation (Policies) Network

*

*

 http://forward-pharma.com/role/DisclosureBasisOfPreparationPolicies
157 Implied Table Table

*

*

 implied:Table
158 Basis of Preparation Abstract fwp:BasisOfPreparationAbstract
159 Basis of preparation Concept (Text Block (HTML)) For Period fwp:DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock
160 Basis of consolidation Concept (Text Block (HTML)) For Period fwp:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock
161 Translation from functional currencies to presentation currency Concept (Text Block (HTML)) For Period fwp:DescriptionOfAccountingPolicyForTranslationFromFunctionalCurrenciesToPresentationCurrencyPolicyTextBlock
162 Foreign currencies transactions and balances Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
163 Revenue recognition Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
164 Share-based payments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
165 Employee benefits Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
166 Operating Expenses in the Statement of Profit or Loss Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory
167 Government grants Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants
168 Current and deferred income taxes Concept (Text Block (HTML)) For Period fwp:DescriptionOfAccountingPolicyForIncomeTaxAndDeferredTaxPolicyTextBlock
169 Equipment Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
170 Financial Instruments and the adoption of IFRS 9 Financial Instruments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
171 Financial Liabilities Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory
172 Consolidated statement of cash flow Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForCashFlowsExplanatory
173 30203 - Disclosure - Basis of Preparation (Tables) Network

*

*

 http://forward-pharma.com/role/DisclosureBasisOfPreparationTables
174 Implied Table Table

*

*

 implied:Table
175 Basis of Preparation Abstract fwp:BasisOfPreparationAbstract
176 Schedule of judgments made in applying accounting policies Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
177 Schedule of items are subject to a high degree of estimation uncertainty and are significant to the financial statements: Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAssetsAndLiabilitiesWithSignificantRiskOfMaterialAdjustmentExplanatory
178 30303 - Disclosure - Results for the Year (Tables) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearTables
179 Implied Table Table

*

*

 implied:Table
180 Results for the Year Abstract fwp:DisclosureOfOperatingResultsAbstract
181 Schedule of staff costs Concept (Text Block (HTML)) For Period fwp:DisclosureOfStaffCostsTableTextBlock
182 Summary of the activity for equity awards in the form of options and warrants and the weighted average exercise price (WAEP): Concept (Text Block (HTML)) For Period fwp:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAndWarrantsTableTextBlock
183 Summary of range of exercise prices Concept (Text Block (HTML)) For Period fwp:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAndWarrantsTableTextBlock
184 Summary of the inputs to the model used to value equity awards, including modifications of equity awards, as well as the average fair value per option or warrant awarded or modified Concept (Text Block (HTML)) For Period fwp:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsAndWarrantsGrantedDuringPeriodTableTextBlock
185 Summary of deferred share activity Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
186 Summary of share-based compensation expense included within operating results Concept (Text Block (HTML)) For Period ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss
187 Schedule of major components of income tax benefit (expense) Concept (Text Block (HTML)) For Period fwp:ScheduleOfComponentsOfIncomeTaxBenefitReportedInProfitAndLossTableTextBlock
188 Schedule of income tax benefit (expense) reconciliation Concept (Text Block (HTML)) For Period fwp:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
189 Schedule of unrecognized deferred tax assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDeferredTaxesExplanatory
190 Schedule of unrecognized deductible temporary difference Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
191 Schedule of net (loss) income attributable to ordinary shareholders Concept (Text Block (HTML)) For Period ifrs-full:EarningsPerShareExplanatory
192 30403 - Disclosure - Operating Assets and Liabilities (Tables) Network

*

*

 http://forward-pharma.com/role/DisclosureOperatingAssetsAndLiabilitiesTables
193 Implied Table Table

*

*

 implied:Table
194 Operating Assets and Liabilities Abstract fwp:OperatingAssetsAndLiabilitiesAbstract
195 Summary of depreciation expense Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory
196 Summary of prepaid expenses Concept (Text Block (HTML)) For Period fwp:DisclosureOfPrepaidExpensesExplanatory
197 Summary of other receivables Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory
198 Summary of accrued liabilities Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory
199 30503 - Disclosure - Capital Structure and Related Items (Tables) Network

*

*

 http://forward-pharma.com/role/DisclosureCapitalStructureAndRelatedItemsTables
200 Disclosure of nature and extent of risks arising from financial instruments [table] Table

*

*

 ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable
201 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
202 Risks [member] Member ifrs-full:TypesOfRisksMember
203 Foreign Currency Member ifrs-full:CurrencyRiskMember
204 Capital Structure and Financial Risk and Related Items LineItems ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems
205 Summary of the Company's share activity Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
206 Summary of impact on the Group's statement of profit or loss of possible changes in the USD, GBP and Euro exchange rates against the Group's functional currencies, USD, DKK and Euro Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory
207 Schedule of financial assets at amortized cost Concept (Text Block (HTML)) For Period fwp:DisclosureOfFinancialAssetsAtAmortizedCostTextBlock
208 Summary of financial liabilities at amortized cost Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
209 30603 - Disclosure - Other Disclosures (Tables) Network

*

*

 http://forward-pharma.com/role/DisclosureOtherDisclosuresTables
210 Implied Table Table

*

*

 implied:Table
211 Other Disclosures Abstract ifrs-full:AdditionalInformationAbstract
212 Summary of transactions with related parties, Excluding VAT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
213 40101 - Disclosure - Corporate information (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureCorporateInformationDetails
214 Notes to Consolidated Financial Statements [Table] Table

*

*

 fwp:NotesToConsolidatedFinancialStatementsTable
215 IFRS Statement Scenario [Axis] Axis fwp:IfrsStatementScenarioAxis
216 IFRS Scenario Unspecified [Domain] Member fwp:IfrsScenarioUnspecifiedDomain
217 Forecast Member fwp:IfrsScenarioForecastMember
218 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
219 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
220 Exclusive license Member fwp:ExclusiveLicenseContingentLiabilityMember
221 Legal Entity [Axis] Axis dei:LegalEntityAxis
222 Entity [Domain] Member dei:EntityDomain
223 Biogen Member fwp:BiogenMember
224 HoldCo Member fwp:HoldcoMember
225 Foundation Member fwp:FwpFondenMember
226 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
227 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
228 Aditech Member fwp:AditechPharmaAgMember
229 Biogen Member fwp:BiogenMember
230 Foundation Member fwp:FwpFondenMember
231 Subsidiaries [axis] Axis ifrs-full:SignificantInvestmentsInSubsidiariesAxis
232 Entity's total for subsidiaries [member] Member ifrs-full:EntitysTotalForSubsidiariesMember
233 FWP IP Member fwp:FwpIpMember
234 IFRS Subsidiary Sale Of Stock [Axis] Axis fwp:IfrsSubsidiarySaleOfStockAxis
235 IFRS Sale Of Stock Name Of Transaction [Domain] Member fwp:IfrsSaleOfStockNameOfTransactionDomain
236 IPO Member fwp:IfrsIpoMember
237 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
238 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
239 ADS Member fwp:AmericanDepositarySharesMember
240 IFRS Litigation Case [Axis] Axis fwp:IfrsLitigationCaseAxis
241 IFRS Litigation Case Type [Domain] Member fwp:IfrsLitigationCaseTypeDomain
242 Interference Proceeding Member fwp:InterferenceProceedingMember
243 Notes To Consolidated Financial Statements [Line Items] LineItems fwp:NotesToConsolidatedFinancialStatementsLineItems
244 Number of subsidiaries Concept (Integer) As Of fwp:NumberOfDirectAndIndirectOwnedSubsidiaries
245 Subsidiaries who entered into an agreement Concept (Integer) As Of fwp:NumberOfSubsidiariesWithAgreement
246 Number of board members Concept (Integer) As Of fwp:NumberOfBoardMembers
247 Number of independent directors Concept (Integer) As Of fwp:NumberOfIndependentDirectors
248 Number of directors Concept (Integer) As Of fwp:NumberOfDirectors
249 Number of company appointed directors Concept (Integer) As Of fwp:NumberOfCompanyAppointedDirectors
250 Consideration for capital stock Concept (Monetary) As Of Credit ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
251 Group contribution as initial capitalization of the Foundation Concept (Monetary) For Period Credit fwp:InitialCapitalizationContribution
252 Capital commitments Concept (Monetary) As Of Credit ifrs-full:CapitalCommitments
253 Share split ratio Concept (Pure) For Period fwp:StockSplitConversionRatio
254 Per share nominal value of an ordinary share Concept (Share) As Of ifrs-full:ParValuePerShare
255 Annulment of ordinary shares (as a percent) Concept (Percent) For Period fwp:PercentageOfReductionInOrdinaryShares
256 Shareholder distribution (Capital Reduction) Concept (Monetary) For Period Debit ifrs-full:ReductionOfIssuedCapital
257 Non-refundable fee Concept (Monetary) For Period Credit fwp:LicenseAgreementNonRefundableFee
258 Obligation payable Concept (Monetary) As Of Credit fwp:ContingentLiabilityObligationPayable
259 Royalty percentage Concept (Percent) For Period fwp:PercentageOfRoyaltyToCollect
260 Milligrams of DMF Concept (Integer) For Period fwp:NumberOfMilligramsOfDmf
261 Duration of appeal process Concept (xbrli:durationItemType) For Period fwp:DurationOfAppealProcess
262 Number of share per ADS Concept (Shares) As Of fwp:NumberOfOrdinarySharePerEachAds
263 Number of shares issued Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
264 Gross proceeds from issuance of shares Concept (Monetary) For Period Debit fwp:GrossProceedsFromIssuingShares
265 Underwriting commission percentage Concept (Percent) For Period fwp:UnderwritingCommissionAsPercentageOfGrossProceeds
266 Number of votes per share Concept (Integer) As Of fwp:NumberOfVotePerShare
267 40201 - Disclosure - Basis of Preparation (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureBasisOfPreparationDetails
268 Disclosure of detailed information about basis of preparation [Table] Table

*

*

 fwp:DisclosureOfDetailedInformationAboutBasisOfPreparationTable
269 Range [axis] Axis ifrs-full:RangeAxis
270 Ranges [member] Member ifrs-full:RangesMember
271 Minimum Member ifrs-full:BottomOfRangeMember
272 Maximum Member ifrs-full:TopOfRangeMember
273 Disclosure of detailed information about basis of preparation [Line items] LineItems fwp:DisclosureOfDetailedInformationAboutBasisOfPreparationLineItems
274 Exchange rate gains (losses) Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
275 Expiration period Concept (xbrli:durationItemType) For Period fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod
276 Number of equity awards exceeding ten years Concept (Integer) For Period fwp:NumberEquityAwardsExceedingTenYears
277 Vesting term Concept (xbrli:durationItemType) For Period fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
278 Cost recognized for awards that do not ultimately vest Concept (Monetary) For Period Debit ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
279 Court expenses Concept (Monetary) For Period Debit fwp:CourtExpenses
280 Provision for uncertain tax positions Concept (Monetary) For Period Debit fwp:ProvisionForUncertainTaxPositions
281 Impairment loss Concept (Monetary) For Period Debit ifrs-full:ImpairmentLoss
282 Expected useful lives Concept (xbrli:durationItemType) For Period fwp:UsefulLivesPropertyPlantAndEquipment
283 Vendors who provide extended payment terms Concept (Integer) For Period fwp:NumberOfVendorsProvidingExtendedPaymentTerms
284 40301 - Disclosure - Results for the Year - Staff costs (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearStaffCostsDetails
285 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
286 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
287 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
288 Certain members of senior management Member fwp:CertainMembersOfSeniorManagementMember
289 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
290 Number of business units Concept (Integer) For Period fwp:IfrsNumberOfOperatingSegments
291 Wages and salaries Concept (Monetary) For Period Debit ifrs-full:WagesAndSalaries
292 Social taxes and benefits Concept (Monetary) For Period Debit ifrs-full:SocialSecurityContributions
293 Share based payment (Note 3.3) Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
294 Total employee benefits expense Concept (Monetary) For Period Debit ifrs-full:EmployeeBenefitsExpense
295 Research and development costs Concept (Monetary) For Period Debit fwp:StaffCostsIncludedInResearchAndDevelopmentCosts
296 General and administrative costs Concept (Monetary) For Period Debit fwp:StaffCostsIncludedInGeneralAndAdministrativeCosts
297 Total Concept (Monetary) For Period Debit fwp:TotalStaffCostsIncludedInProfitAndLoss
298 Short term employee benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
299 Severance benefits Concept (Monetary) For Period Debit ifrs-full:TerminationBenefitsExpense
300 Share based payment Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
301 Total compensation paid to key management personnel Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
302 Amount of reversal of share-based compensation expense Concept (Monetary) For Period Credit fwp:ReversalOfPreviouslyRecognizedShareBasedCompensation
303 40302 - Disclosure - Results for the Year - Share- based compensation (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearShareBasedCompensationDetails
304 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
305 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
306 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
307 Unsuccessful outcome of Interference Proceeding Member ifrs-full:CommencementOfMajorLitigationMember
308 Range [axis] Axis ifrs-full:RangeAxis
309 Ranges [member] Member ifrs-full:RangesMember
310 Minimum Member ifrs-full:BottomOfRangeMember
311 Maximum Member ifrs-full:TopOfRangeMember
312 IFRS Title Of Individual [Axis] Axis fwp:IfrsTitleOfIndividualAxis
313 IFRS Relationship To Entity [Domain] Member fwp:IfrsRelationshipToEntityDomain
314 Certain employees, board members and consultants Member fwp:CertainEmployeesBoardMembersAndConsultantsMember
315 Board of Directors Member fwp:IfrsBoardOfDirectorsMember
316 Employees Member fwp:EmployeesMember
317 Consultants Member fwp:ConsultantsMember
318 Non employee consultants Member fwp:NonEmployeeConsultantsMember
319 Chief Executive Officer Member fwp:IfrsChiefExecutiveOfficerMember
320 Former Employees Member fwp:FormerEmployeesMember
321 Chief Financial Officer Member fwp:IfrsChiefFinancialOfficerMember
322 Director Member fwp:IfrsDirectorMember
323 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
324 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
325 Warrants Member fwp:IfrsWarrantMember
326 $1.36 Warrants Member fwp:ExercisePrice1.36WarrantsMember
327 $1.49 Warrants Member fwp:ExercisePrice1.49WarrantsMember
328 Deferred shares Member fwp:DeferredSharesMember
329 June 2017 Deferred Shares Member fwp:June2017DeferredSharesMember
330 Share Options Member fwp:IfrsEmployeeStockOptionMember
331 2018 Option Member fwp:Options2018Member
332 June 2017 Options Member fwp:June2017ShareOptionsMember
333 March 2017 Options Member fwp:March2017OptionsMember
334 June 2016 Warrants Member fwp:June2016WarrantsMember
335 Expiring Awards Member fwp:ExpiringAwardsMember
336 Replacement Awards Member fwp:ReplacementAwardsMember
337 2018 Vested Options Member fwp:VestedOptions2018Member
338 Consultant Options Member fwp:ConsultantOptionsMember
339 Consultant Options, Exercise Price One Member fwp:ConsultantOptionsExercisePriceOneMember
340 Consultant Options, Exercise Price Two Member fwp:ConsultantOptionsExercisePriceTwoMember
341 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
342 Number of ordinary shares per each ADS prior to the share split Concept (Shares) For Period fwp:NumberOfOrdinarySharesPerEachAdsPriorToShareSplit
343 Number of ordinary shares at the time of share split per each ADS Concept (Shares) As Of fwp:NumberOfOrdinarySharesPerEachAdsAtShareSplit
344 Number of ordinary shares per each ADS after Capital Reduction Concept (Shares) For Period fwp:NumberOfOrdinarySharesPerEachAdsAfterCapitalReduction
345 Ordinary shares available for grant under the Equity Plan Concept (Shares) As Of fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
346 Shares available for future grant under the Equity Plan Concept (Shares) For Period fwp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfFutureSharesAvailableForGrantUnderEquityPlan
347 Warrants available for future grant, inclusive of shares available for future grant under the Equity Plan Concept (Shares) For Period fwp:ShareBasedCompensationPaymentAwardNumberOfFutureWarrantsAvailableForGrantUnderDanishCorporateLawInclusiveOfSharesAvailableForFutureGrantOfEquityPlan
348 Deferred shares available for future grant, inclusive of shares available for future grant under the Equity Plan Concept (Shares) For Period fwp:ShareBasedCompensationPaymentAwardNumberOfFutureDeferredSharesAvailableForGrantUnderDanishCorporateLawInclusiveOfSharesAvailableForFutureGrantOfEquityPlan
349 Number of options granted Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
350 Number of options granted (after share split) Concept (Decimal) For Period fwp:NumberOfShareOptionsGrantedInShareBasedPaymentArrangementAfterShareSplit
351 Exercise price of outstanding share options Concept (Monetary) As Of ifrs-full:ExercisePriceOfOutstandingShareOptions
352 Exercise price of outstanding share options (after share split) Concept (Share) As Of fwp:ExercisePriceOfOutstandingShareOptionsAfterShareSplit
353 Percentage of shares reduced in subscription of share options Concept (Percent) For Period fwp:PercentageOfSharesReducedInSubscriptionOfShareOptions
354 Number of share options reduced (after share split) Concept (Shares) For Period fwp:NumberOfShareOptionsReducedAfterShareSplit
355 Percentage of shares reduced in subscription of deferred shares Concept (Percent) For Period fwp:PercentageOfSharesReducedInSubscriptionOfDeferredShares
356 Number of deferred shares reduced (after share split) Concept (Shares) For Period fwp:NumberOfDeferredSharesReducedAfterShareSplit
357 Expiration period Concept (xbrli:durationItemType) For Period fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod
358 Aggregate fair value of options granted Concept (Monetary) For Period Debit fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
359 Due to option holders as a result of Capital Reduction Concept (Monetary) As Of Credit fwp:DueToOptionHoldersAsResultOfCapitalReduction
360 Amount paid to option holders as a result of the Capital Reduction Concept (Monetary) For Period Credit fwp:AmountPaidToOptionHoldersAsResultOfCapitalReduction
361 Remaining cash payment to be paid as a result of capital reduction Concept (Monetary) As Of Credit fwp:RemainingCashPaymentToBePaidAsResultOfCapitalReduction
362 Number of deferred shares granted (after share split) Concept (Decimal) For Period fwp:NumberOfDeferredSharesGrantedAfterShareSplit
363 Number of deferred shares vest in the event of favourable conclusion of the Interference Proceedings Concept (Decimal) As Of fwp:NumberOfDeferredSharesVestInEventOfFavourableConclusionOfInterferenceProceedings
364 Number of deferred shares vest in the event of Interference Proceedings (after share split) Concept (Decimal) As Of fwp:NumberOfDeferredSharesVestInEventOfFavourableConclusionOfInterferenceProceedingsAfterShareSplit
365 Due to the deferred share holders of the company as a result of Capital Reduction Concept (Monetary) As Of Credit fwp:DueToHoldersOfShareBasedAwardsAsResultOfCapitalReduction
366 Number of deferred shares outstanding Concept (Decimal) As Of fwp:NumberOfDeferredSharesOutstanding
367 Number of deferred shares would vest upon successful outcome of the interference proceeding Concept (Decimal) For Period fwp:NumberOfDeferredSharesWouldVestUponSuccessfulOutcomeOfInterferenceProceeding
368 Number of deferred shares expired Concept (Decimal) For Period fwp:NumberOfDeferredSharesExpiredUponUnsuccessfulOutcomeOfInterferenceProceeding
369 Potential antidilution payments to the holders Concept (Monetary) As Of Credit fwp:PotentialAntidilutionPaymentsToHolders
370 Number of board members who terminated their roles Concept (Integer) For Period fwp:NumberOfTerminatedBoardMembers
371 Number of equity awards forfeited Concept (Decimal) For Period ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
372 Number of equity awards forfeited (after share split) Concept (Decimal) For Period fwp:NumberOfEquityAwardsForfeitedAfterShareSplit
373 Number of options or warrants forfeited Concept (Decimal) For Period fwp:NumberOfOptionsOrWarrantsForfeited
374 Number of options or warrants forfeited (after share split) Concept (Decimal) For Period fwp:NumberOfOptionsOrWarrantsForfeitedAfterShareSplit
375 Number of options or warrants allowing to hold after modification Concept (Decimal) For Period fwp:NumberOfOptionsOrWarrantsAllowingToHoldAfterModification
376 Number of options or warrants allowing to hold after modification (after share split) Concept (Decimal) For Period fwp:NumberOfOptionsOrWarrantsAllowingToHoldAfterModificationAfterShareSplit
377 Annulment of ordinary shares (as a percent) Concept (Percent) For Period fwp:PercentageOfReductionInOrdinaryShares
378 Cash payment to award holders as a result of annulment of shares Concept (Monetary) For Period Credit fwp:CashPaymentToAwardHoldersForAnnulmentOfShares
379 Reduction in number of outstanding awards as a result of annulment of shares Concept (Decimal) For Period fwp:ReductionInNumberOfOutstandingAwardsAsResultOfAnnulmentOfShares
380 Expense recognized when Award is negatively affected by Amendment Concept (Monetary) For Period Debit fwp:ExpenseRecognizedWhenAwardFairValueWasNegativelyAffectedByAmendment
381 Exercise price Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
382 Exercise price Concept (Monetary) As Of fwp:ExercisePriceOfOutstandingShareOptionsAndWarrants
383 Option exercise price (after share split) Concept (Monetary) For Period fwp:OptionExercisePriceAfterShareSplit
384 Holders of deferred shares need to remit upon issuance Concept (Share) For Period fwp:HolderOfDeferredSharesNeedToRemit
385 Number of warrants granted Concept (Decimal) As Of fwp:NumberOfWarrantsGranted
386 Number of warrants granted (after share split) Concept (Shares) For Period fwp:NumberOfWarrantsGrantedAfterShareSplit
387 Warrants yield proceeds to the company Concept (Monetary) For Period Debit fwp:WarrantExerciseProceeds
388 Fair value of an ordinary share of the Company on the date of exercise Concept (Monetary) For Period Credit fwp:FairValueOfSharesOnDateOfExercise
389 Fair value of ordinary shares of the company on the date of exercise (after share split) Concept (Monetary) For Period Credit fwp:FairValueOfSharesOnDateOfExerciseAfterShareSplit
390 Warrants exercised Concept (Decimal) For Period fwp:NumberOfWarrantsExercised
391 Warrants exercised (after share split) Concept (Decimal) For Period fwp:NumberOfWarrantsExercisedAfterShareSplit
392 Exercise price of warrants Concept (Monetary) As Of Debit fwp:ExercisePriceOfWarrants
393 Exercise price of warrants (after share split) Concept (Monetary) For Period Debit fwp:ExercisePriceOfWarrantsGrantedAfterShareSplit
394 Vesting term Concept (xbrli:durationItemType) For Period fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
395 Reduction of issued capital Concept (Monetary) For Period Debit ifrs-full:ReductionOfIssuedCapital
396 Number of options vested Concept (Decimal) As Of fwp:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
397 Vesting of option with a exercise price of $2.83 Concept (Decimal) As Of fwp:NumberOfShareOptionsVestedInShareBasedPaymentArrangementWithStatedExercisePrice
398 Exercise price of shares vested Concept (Monetary) As Of Debit fwp:ExercisePriceOfSharesVested
399 Weighted average fair value per consultant option applied for recognition of an expense (after share split) Concept (Monetary) For Period fwp:WeightedAverageFairValueAtMeasurementDatePerConsultantOptionShareOptionsGrantedAfterShareSplit
400 Expense recognized during the period Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
401 Amount of reversal of share-based compensation expense Concept (Monetary) For Period Credit fwp:ReversalOfPreviouslyRecognizedShareBasedCompensation
402 Granting of share options or warrants to replace expiring awards Concept (Decimal) As Of fwp:ShareOptionsOrWarrantsGrantedToReplaceExpiringAwards
403 Granting of share options or warrants to replace expiring awards (after share split) Concept (Decimal) As Of fwp:ShareOptionsOrWarrantsGrantedToReplaceExpiringAwardsAfterShareSplit
404 Expiring Awards Concept (Decimal) For Period fwp:NumberOfExpiringOptionsAndOtherEquityInstrumentsShareBasedPaymentArrangement
405 Expiring awards (after share split) Concept (Decimal) For Period fwp:NumberOfExpiringOptionsAndOtherEquityInstrumentsShareBasedPaymentArrangementAfterShareSplit
406 Employees receiving options Concept (Integer) For Period fwp:NumberOfEmployeesGrantedOptions
407 Number of former employees Concept (Integer) For Period fwp:NumberOfFormerEmployees
408 Consulting agreement term Concept (xbrli:durationItemType) For Period fwp:ConsultingAgreementTerm
409 Granting of deferred shares Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
410 40303 - Disclosure - Results for the Year - Options and warrants and the weighted average exercise (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearOptionsAndWarrantsAndWeightedAverageExerciseDetails
411 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
412 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
413 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
414 Options and warrants Member fwp:OptionsAndWarrantsMember
415 IFRS Title Of Individual [Axis] Axis fwp:IfrsTitleOfIndividualAxis
416 IFRS Relationship To Entity [Domain] Member fwp:IfrsRelationshipToEntityDomain
417 Key Management Personnel Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
418 Employees and consultants Member fwp:EmployeesAndConsultantsMember
419 Non employee consultants Member fwp:NonEmployeeConsultantsMember
420 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
421 Outstanding at beginning of year Concept (Decimal) As Of fwp:NumberOfOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement
422 Granted Concept (Decimal) For Period fwp:NumberOfOptionsAndOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement
423 Expiring Awards Concept (Decimal) For Period fwp:NumberOfExpiringOptionsAndOtherEquityInstrumentsShareBasedPaymentArrangement
424 Exercised Concept (Decimal) For Period fwp:NumberOfShareOptionsAndOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement
425 Expired and forfeited Concept (Decimal) For Period fwp:NumberOfShareOptionsAndOtherEquityInstrumentsExpiredAndForfeitedInShareBasedPaymentArrangement
426 Forfeited Concept (Decimal) For Period fwp:NumberOfShareOptionsAndOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangement
427 Effect of the Amendment and the June 2017 Award Adjustment Concept (Decimal) For Period fwp:NumberOfShareOptionsAndOtherEquityInstrumentsEffectOfAmendmentInShareBasedPaymentArrangement
428 Outstanding at end of year Concept (Decimal) As Of fwp:NumberOfOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement
429 Exercisable Concept (Decimal) For Period fwp:NumberOfShareOptionsAndOtherEquityInstrumentsExercisableInShareBasedPaymentArrangement
430 Outstanding at beginning of year Concept (Monetary) As Of fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement
431 Granted Concept (Monetary) For Period fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement
432 Expiring Awards Concept (Monetary) For Period fwp:WeightedAverageExercisePriceOfExpiringShareOptionsAndOtherEquityInstrumentsInShareBasedPaymentArrangement
433 Exercised Concept (Monetary) For Period fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement
434 Expired and forfeited Concept (Monetary) For Period fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsExpiredAndForfeitedInShareBasedPaymentArrangement
435 Forfeited Concept (Monetary) For Period fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangement
436 Effect of the Amendment Concept (Monetary) For Period fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsEffectOfAmendmentInShareBasedPaymentArrangement
437 Outstanding at end of year Concept (Monetary) As Of fwp:WeightedAverageExercisePriceOfShareOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement
438 Weighted average remaining contractual life of equity awards Concept (xbrli:durationItemType) For Period fwp:WeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAndOtherEquityInstruments
439 40304 - Disclosure - Results for the Year - Range of exercise (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearRangeOfExerciseDetails
440 Disclosure of range of exercise prices of outstanding share options [table] Table

*

*

 ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable
441 Ranges of exercise prices for outstanding share options [axis] Axis ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis
442 Ranges of exercise prices for outstanding share options [member] Member ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember
443 $0.0015 to $0.12 Member fwp:ExercisePriceRangeOneMember
444 $0.75 to $0.95 Member fwp:ExercisePriceRangeTwoMember
445 $1.24 to $1.80 Member fwp:ExercisePriceRangeThreeMember
446 $2.09 to $2.83 Member fwp:ExercisePriceRangeFourMember
447 $3.05 to $3.77 Member fwp:ExercisePriceRangeFiveMember
448 $4.51 to $6.92 Member fwp:ExercisePriceRangeSixMember
449 $14.13 Member fwp:ExercisePriceRangeSevenMember
450 Range [axis] Axis ifrs-full:RangeAxis
451 Ranges [member] Member ifrs-full:RangesMember
452 Minimum Member ifrs-full:BottomOfRangeMember
453 Maximum Member ifrs-full:TopOfRangeMember
454 Disclosure of range of exercise prices of outstanding share options [line items] LineItems ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems
455 Exercise price Concept (Monetary) As Of fwp:ExercisePriceOfOutstandingShareOptionsAndWarrants
456 Outstanding equity awards Concept (Decimal) As Of fwp:NumberOfOptionsAndOtherEquityInstrumentsOutstandingInShareBasedPaymentArrangement
457 Dividend yield (%) Concept (Pure) For Period fwp:ExpectedDividendAsPercentageShareOptionsAndWarrantsGranted
458 Expected volatility (%) Concept (Pure) For Period fwp:DescriptionOfExpectedVolatilityShareOptionsAndWarrantsGranted
459 Risk-free interest rate (%) Concept (Pure) For Period fwp:DescriptionOfRiskFreeInterestRateShareOptionsAndWarrantsGranted
460 Expected life of the equity award (years) Concept (xbrli:durationItemType) For Period fwp:DescriptionOfLifeShareOptionsAndWarrantsGranted
461 Share price Concept (Monetary) As Of Debit fwp:SharePriceShareOptionsAndWarrantsGranted
462 Average fair value per option or warrant granted ($) Concept (Monetary) As Of Credit fwp:AverageFairValueSharePriceShareOptionsAndWarrantsGranted
463 40305 - Disclosure - Results for the Year - Deferred share activity (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearDeferredShareActivityDetails
464 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
465 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
466 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
467 Deferred shares Member fwp:DeferredSharesMember
468 IFRS Statement Scenario [Axis] Axis fwp:IfrsStatementScenarioAxis
469 IFRS Scenario Unspecified [Domain] Member fwp:IfrsScenarioUnspecifiedDomain
470 Forecast Member fwp:IfrsScenarioForecastMember
471 IFRS Title Of Individual [Axis] Axis fwp:IfrsTitleOfIndividualAxis
472 IFRS Relationship To Entity [Domain] Member fwp:IfrsRelationshipToEntityDomain
473 Key Management Personnel Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
474 Employees and consultants Member fwp:EmployeesAndConsultantsMember
475 Chief Financial Officer Member fwp:IfrsChiefFinancialOfficerMember
476 Chief Executive Officer Member fwp:IfrsChiefExecutiveOfficerMember
477 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
478 Outstanding at beginning of year Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
479 Granted Concept (Decimal) For Period fwp:NumberOfInstrumentsOtherEquityInstrumentsGrantedAfterShareSplit
480 Transfer Concept (Decimal) For Period fwp:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
481 Vested and issued Concept (Decimal) For Period fwp:NumberOfOtherEquityInstrumentsVestedAndIssuedInShareBasedPaymentArrangement
482 Forfeited Concept (Decimal) For Period ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
483 Effect of the Amendment and the Deferred Share Adjustment Concept (Decimal) For Period fwp:NumberOfOtherEquityInstrumentsEffectOfAmendmentTransferredInShareBasedPaymentArrangement
484 Outstanding at end of year Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
485 Vested and unissued Concept (Decimal) For Period fwp:NumberOfOtherEquityInstrumentsVestedAndUnissuedInShareBasedPaymentArrangement
486 Research and development costs Concept (Monetary) For Period Debit fwp:ShareBasedCompensationExpenseIncludedInResearchAndDevelopmentCosts
487 General and administrative costs Concept (Monetary) For Period Debit fwp:ShareBasedCompensationExpenseIncludedInGeneralAndAdministrativeCosts
488 Total Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
489 Exercise price Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
490 Vesting term Concept (xbrli:durationItemType) For Period fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
491 Number of deferred shares expired Concept (Decimal) For Period fwp:NumberOfOtherEquityInstrumentsExpired
492 40306 - Disclosure - Results for the Year - Major components of income tax expense (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearMajorComponentsOfIncomeTaxExpenseDetails
493 Implied Table Table

*

*

 implied:Table
494 Results for the Year Abstract fwp:DisclosureOfOperatingResultsAbstract
495 Current income tax benefit (expense) Concept (Monetary) For Period Debit ifrs-full:CurrentTaxExpenseIncome
496 Deferred income tax benefit (expense) Concept (Monetary) For Period ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
497 Total income tax benefit (expense) Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
498 40307 - Disclosure - Results for the Year - Income tax - Deferred tax (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearIncomeTaxDeferredTaxDetails
499 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
500 Temporary difference, unused tax losses and unused tax credits [axis] Axis ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
501 Temporary difference, unused tax losses and unused tax credits [member] Member ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
502 Net operating loss carryforwards Member ifrs-full:UnusedTaxLossesMember
503 Tax effect of tax loss carry forwards Member ifrs-full:UnusedTaxCreditsMember
504 Other temporary differences regarding share-based payment etc. Member ifrs-full:TemporaryDifferenceMember
505 Share-based payment Member fwp:ShareBasedPaymentMember
506 Other Member ifrs-full:OtherTemporaryDifferencesMember
507 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
508 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
509 Denmark Member ifrs-full:CountryOfDomicileMember
510 Germany Member country:DE
511 Disclosure of temporary difference, unused tax losses and unused tax credits [line items] LineItems ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
512 Income tax expense : Abstract ifrs-full:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract
513 (Loss) income before tax Concept (Monetary) For Period Credit ifrs-full:AccountingProfit
514 Tax benefit (expense) at the Company's statutory income tax rate Concept (Monetary) For Period Debit ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
515 Non-deductible expenses for tax purposes Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
516 Effect of higher tax rate in Germany Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfForeignTaxRates
517 (Unrecognized) recognized deferred tax assets Concept (Monetary) For Period Debit fwp:TaxEffectOfRecognizedAndUnrecognizedDeferredTaxAssets
518 Adjustment related to prior year Concept (Monetary) For Period Debit fwp:TaxEffectOfAdjustmentsForCurrentTaxOfPriorPeriods
519 Total income tax benefit (expense) Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
520 Effective tax rate (as a percent) Concept (Percent) For Period ifrs-full:AverageEffectiveTaxRate
521 Statutory tax rates (as a percent) Concept (Percent) For Period ifrs-full:ApplicableTaxRate
522 Deferred tax Abstract ifrs-full:DeferredTaxAssetsAndLiabilitiesAbstract
523 Recognized tax benefits within the consolidated statement of changes in shareholders' equity Concept (Monetary) For Period Debit ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions
524 Unrecognized deferred tax assets, net Concept (Monetary) As Of Debit fwp:UnrecognizedDeferredTaxAssetsNet
525 Unrecognized deductible temporary differences Concept (Monetary) As Of Credit ifrs-full:NetDeferredTaxLiabilities
526 Percentage of threshold taxable income limit to use tax carry forwards Concept (Percent) For Period fwp:PercentageOfThresholdTaxableIncomeToUseTaxCarryForwards
527 Threshold taxable income limit to use tax carry forwards Concept (Monetary) For Period Debit fwp:ThresholdTaxableIncomeLimitToUseTaxLossCarryForwards
528 Percentage of taxable income above threshold limit to use tax carry forwards Concept (Percent) For Period fwp:PercentageOfTaxableIncomeAboveThresholdLimitToUseTaxCarryForwards
529 Period of tax audits Concept (xbrli:durationItemType) For Period fwp:PeriodOfTaxAudits
530 Number of audits Concept (Integer) For Period fwp:NumberOfAudits
531 Cash payments to equity awards Concept (Monetary) For Period Debit fwp:CashPaymentsToEquityAwardsDeduction
532 40308 - Disclosure - Results for the Year - Net (loss) income per share (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureResultsForYearNetLossIncomePerShareDetails
533 Implied Table Table

*

*

 implied:Table
534 Results for the Year Abstract fwp:DisclosureOfOperatingResultsAbstract
535 Annulment of ordinary shares (as a percent) Concept (Percent) For Period fwp:PercentageOfReductionInOrdinaryShares
536 Premium (as a percent) Concept (Percent) For Period fwp:PercentageOfSharePremium
537 Share split (ratio) Concept (Pure) For Period fwp:StockholdersEquityStockSplitConversionRatio
538 Net (loss) income attributable to ordinary shareholders of the Parent used for computing basic and diluted net (loss) income per share Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
539 Weighted average number of ordinary shares used for basic per share amounts Concept (Shares) For Period ifrs-full:WeightedAverageShares
540 Dilutive effect of outstanding options, warrants and deferred shares Concept (Shares) For Period ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares
541 Weighted average number of ordinary shares used for diluted per share amounts Concept (Shares) For Period ifrs-full:AdjustedWeightedAverageShares
542 Net (loss) income per share basic Concept (Share) For Period ifrs-full:BasicEarningsLossPerShare
543 Net (loss) income per share diluted Concept (Share) For Period ifrs-full:DilutedEarningsLossPerShare
544 Anti-dilutive securities Concept (Shares) For Period fwp:IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
545 40401 - Disclosure - Operating Assets and Liabilities - Summary of depreciation expense (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOperatingAssetsAndLiabilitiesSummaryOfDepreciationExpenseDetails
546 Implied Table Table

*

*

 implied:Table
547 Operating Assets and Liabilities Abstract fwp:OperatingAssetsAndLiabilitiesAbstract
548 Research and development costs Concept (Monetary) For Period Debit fwp:ResearchAndDevelopmentCostsPropertyPlantAndEquipment
549 General and administrative costs Concept (Monetary) For Period Debit fwp:GeneralAndAdministrativeCostsPropertyPlantAndEquipment
550 Depreciation expense, Total Concept (Monetary) For Period ifrs-full:DepreciationPropertyPlantAndEquipment
551 Impairment loss included in research and development costs Concept (Monetary) For Period Debit fwp:ImpairmentLossIncludedInResearchAndDevelopmentExpense
552 40402 - Disclosure - Operating Assets and Liabilities - Prepayments (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOperatingAssetsAndLiabilitiesPrepaymentsDetails
553 Implied Table Table

*

*

 implied:Table
554 Operating Assets and Liabilities Abstract fwp:OperatingAssetsAndLiabilitiesAbstract
555 Insurance Concept (Monetary) As Of Debit fwp:InsurancePayments
556 Other Concept (Monetary) As Of Debit fwp:OtherPrepaidExpenses
557 Total Concept (Monetary) As Of Debit ifrs-full:Prepayments
558 40403 - Disclosure - Operating Assets and Liabilities - Other receivables (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherReceivablesDetails
559 Implied Table Table

*

*

 implied:Table
560 Operating Assets and Liabilities Abstract fwp:OperatingAssetsAndLiabilitiesAbstract
561 Value added tax receivables ("VAT") Concept (Monetary) As Of Debit ifrs-full:ValueAddedTaxReceivables
562 Other receivables Concept (Monetary) As Of Debit ifrs-full:OtherReceivables
563 Total Concept (Monetary) As Of Debit ifrs-full:OtherCurrentReceivables
564 40404 - Disclosure - Operating Assets and Liabilities - Accrued liabilities (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOperatingAssetsAndLiabilitiesAccruedLiabilitiesDetails
565 Implied Table Table

*

*

 implied:Table
566 Operating Assets and Liabilities Abstract fwp:OperatingAssetsAndLiabilitiesAbstract
567 Accrued amounts due to equity award holders (Note 3.3) Concept (Monetary) As Of Credit fwp:AccruedShareBasedPaymentsCurrent
568 Professional advisors Concept (Monetary) As Of Credit fwp:AccruedProfessionalFeeCurrent
569 Other Concept (Monetary) As Of Credit fwp:OtherAccruedLiabilityCurrent
570 Total Concept (Monetary) As Of Credit ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
571 40501 - Disclosure - Capital Structure and Financial Risk and Related Items - Equity and Capital Management (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureCapitalStructureAndFinancialRiskAndRelatedItemsEquityAndCapitalManagementDetails
572 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
573 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
574 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
575 Deferred shares Member fwp:DeferredSharesMember
576 Warrants Member fwp:IfrsWarrantMember
577 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
578 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
579 Ordinary shares Member ifrs-full:OrdinarySharesMember
580 Share capital LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
581 Summary of the Company's share activity Abstract ifrs-full:ReconciliationOfNumberOfSharesOutstandingAbstract
582 Balance at the beginning Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
583 Increase decrease in number of shares outstanding Concept (Shares) For Period ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
584 Capital Reduction (in shares) Concept (Shares) For Period fwp:AnnulmentOfSharesOnAccountOfCapitalReduction
585 Balance at the end Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
586 Shareholder distribution (Capital Reduction) Concept (Monetary) For Period Debit ifrs-full:ReductionOfIssuedCapital
587 Annulment of ordinary shares outstanding (as a percent) Concept (Percent) For Period fwp:PercentageOfReductionInOrdinaryShares
588 Capital Reduction payment per share post Share Split Concept (Share) For Period fwp:PaymentOnAccountOfCapitalReduction
589 Proceeds from issuing shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
590 Par value per share Concept (Share) As Of ifrs-full:ParValuePerShare
591 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
592 40502 - Disclosure - Capital Structure and Financial Risk and Related Items - Financial risk factors (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureCapitalStructureAndFinancialRiskAndRelatedItemsFinancialRiskFactorsDetails
593 Disclosure of risk management strategy related to hedge accounting [table] Table

*

*

 ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable
594 Currency [Axis] Axis srt:CurrencyAxis
595 All Currencies [Domain] Member currency:AllCurrenciesDomain
596 USD Member currency:USD
597 GBP Member currency:GBP
598 EUR Member us-gaap:EurodollarMember
599 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
600 Risks [member] Member ifrs-full:TypesOfRisksMember
601 Foreign Currency Member ifrs-full:CurrencyRiskMember
602 Financial risk factors LineItems ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems
603 Possible change increase (as a percentage) Concept (Percent) As Of fwp:PercentageOfReasonablyPossibleIncreaseInRiskAssumption
604 Possible change decrease (as a percentage) Concept (Percent) As Of fwp:PercentageOfReasonablyPossibleDecreaseInRiskAssumption
605 Increase (decrease) to profit and loss due to increase in risk percentage Concept (Monetary) For Period Credit fwp:IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleIncreaseInDesignatedRiskComponent
606 Increase (decrease) to profit and loss due to decrease in risk percentage Concept (Monetary) For Period Credit fwp:IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent
607 Number of banks Concept (Integer) As Of fwp:NumberOfBanks
608 40503 - Disclosure - Capital Structure and Financial Risk and Related Items - Financial assets (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureCapitalStructureAndFinancialRiskAndRelatedItemsFinancialAssetsDetails
609 Disclosure of financial assets [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsTable
610 Categories of financial assets [axis] Axis ifrs-full:CategoriesOfFinancialAssetsAxis
611 Financial assets, category [member] Member ifrs-full:FinancialAssetsCategoryMember
612 Financial assets at amortized cost Member ifrs-full:FinancialAssetsAtAmortisedCostMember
613 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
614 Financial assets, class [member] Member ifrs-full:FinancialAssetsMember
615 Other receivables Member fwp:OtherReceivablesMember
616 Categories of financial assets recognized LineItems ifrs-full:DisclosureOfFinancialAssetsLineItems
617 Financial assets, at carrying value Concept (Monetary) As Of Debit ifrs-full:FinancialAssets
618 Financial assets, at fair value Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAtFairValue
619 40504 - Disclosure - Capital Structure and Financial Risk and Related Items - Financial liabilities (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureCapitalStructureAndFinancialRiskAndRelatedItemsFinancialLiabilitiesDetails
620 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
621 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
622 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
623 Trade payables Member fwp:TradePayablesMember
624 Categories of financial liabilities [axis] Axis ifrs-full:CategoriesOfFinancialLiabilitiesAxis
625 Financial liabilities, category [member] Member ifrs-full:FinancialLiabilitiesCategoryMember
626 Financial liabilities at amortised cost Member ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember
627 Categories of financial liabilities recognized LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
628 Financial liabilities Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilities
629 Financial liabilities, at fair value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
630 40601 - Disclosure - Other Disclosures - Related party disclosures (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOtherDisclosuresRelatedPartyDisclosuresDetails
631 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
632 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
633 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
634 Consultants Member fwp:ConsultantsMember
635 Board of Directors Member fwp:BoardOfDirectorsMember
636 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
637 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
638 Deferred shares Member fwp:DeferredSharesMember
639 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
640 Number of directors with consulting agreements Concept (Integer) As Of fwp:NumberOfDirectorsWithConsultingAgreements
641 Consulting agreement term Concept (xbrli:durationItemType) For Period fwp:ConsultingAgreementTerm
642 Granted Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
643 Shares outstanding Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
644 Granted (after Share Split) Concept (Decimal) For Period fwp:NumberOfInstrumentsOtherEquityInstrumentsGrantedAfterShareSplit
645 Vesting term Concept (xbrli:durationItemType) For Period fwp:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
646 Purchase of services from NB Concept (Monetary) For Period Debit ifrs-full:ServicesReceivedRelatedPartyTransactions
647 Danish Legal Services Concept (Monetary) For Period Debit fwp:DanishLegalServicesRelatedPartyTransactions
648 Consulting Services Concept (Monetary) For Period Debit fwp:ConsultingServicesRelatedPartyTransactions
649 Amounts owed to related parties Concept (Monetary) As Of Credit ifrs-full:AmountsPayableRelatedPartyTransactions
650 Guarantees provided to related parties Concept (Monetary) For Period ifrs-full:ProvisionOfGuaranteesOrCollateralByEntityRelatedPartyTransactions
651 Guarantees received from related parties Concept (Monetary) For Period ifrs-full:ProvisionOfGuaranteesOrCollateralToEntityRelatedPartyTransactions
652 Compensation Concept (Monetary) For Period Debit fwp:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsWagesAndSalaries
653 Share - based compensation paid Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
654 Payment for partial repurchase of equity awards Concept (Monetary) For Period Debit fwp:PaymentForPartialRepurchaseOfEquityAwards
655 40602 - Disclosure - Other Disclosures - Commitments (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOtherDisclosuresCommitmentsDetails
656 Disclosure of finance lease and operating lease by lessee [table] Table

*

*

 ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable
657 Maturity [axis] Axis ifrs-full:MaturityAxis
658 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
659 2019 Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
660 2020 Member ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember
661 Through May 2022 Member ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember
662 Leasing activities LineItems ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems
663 Minimum lease payments payable under non-cancellable operating lease Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
664 Minimum operating lease payments recognised as expense Concept (Monetary) For Period Debit ifrs-full:MinimumOperatingLeasePayments
665 40603 - Disclosure - Other Disclosures - Contingent liabilities (Details) Network

*

*

 http://forward-pharma.com/role/DisclosureOtherDisclosuresContingentLiabilitiesDetails
666 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
667 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
668 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
669 Addendum Member fwp:AddendumContingentLiabilityMember
670 Exclusive license Member fwp:ExclusiveLicenseContingentLiabilityMember
671 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
672 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
673 Unsuccessful outcome of Interference Proceeding Member ifrs-full:CommencementOfMajorLitigationMember
674 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
675 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
676 Aditech Member fwp:AditechPharmaAgMember
677 Contingent liabilities LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
678 Percentage due of non refundable fee Concept (Percent) For Period fwp:PercentageDueOfNonRefundableFee
679 Obligation payable Concept (Monetary) As Of Credit fwp:ContingentLiabilityObligationPayable
680 Percentage Royalty Due Contingent Liability Concept (Percent) For Period fwp:PercentageRoyaltyDueContingentLiability
681 Contingent liability paid Concept (Monetary) For Period Credit fwp:PaymentOfContingentLiabilities
682 Grant received for product development Concept (Monetary) For Period Credit fwp:GrantReceivedForProductDevelopment
683 Number of deferred shares expired Concept (Decimal) For Period fwp:NumberOfDeferredSharesExpiredUponUnsuccessfulOutcomeOfInterferenceProceeding

*

*